Hiroko Iseoka

717 total citations
15 papers, 476 citations indexed

About

Hiroko Iseoka is a scholar working on Surgery, Molecular Biology and Biomedical Engineering. According to data from OpenAlex, Hiroko Iseoka has authored 15 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 9 papers in Molecular Biology and 4 papers in Biomedical Engineering. Recurrent topics in Hiroko Iseoka's work include Tissue Engineering and Regenerative Medicine (9 papers), Pluripotent Stem Cells Research (7 papers) and Cardiac Structural Anomalies and Repair (3 papers). Hiroko Iseoka is often cited by papers focused on Tissue Engineering and Regenerative Medicine (9 papers), Pluripotent Stem Cells Research (7 papers) and Cardiac Structural Anomalies and Repair (3 papers). Hiroko Iseoka collaborates with scholars based in Japan and France. Hiroko Iseoka's co-authors include Yoshiki Sawa, Shigeru Miyagawa, Emiko Ito, Maki Takeda, Akima Harada, Michiya Matsusaki, Mitsuru Akashi, Satsuki Fukushima, Nagako Sougawa and Atsuhiro Saito and has published in prestigious journals such as Scientific Reports, Acta Biomaterialia and Transplantation.

In The Last Decade

Hiroko Iseoka

15 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroko Iseoka Japan 12 262 249 198 114 71 15 476
Robert C. Coyle United States 10 346 1.3× 332 1.3× 406 2.1× 144 1.3× 86 1.2× 10 684
Pablo Hofbauer Austria 8 365 1.4× 260 1.0× 275 1.4× 108 0.9× 33 0.5× 10 636
Maki Takeda Japan 15 364 1.4× 202 0.8× 172 0.9× 75 0.7× 73 1.0× 35 605
Jason Tchao United States 8 205 0.8× 128 0.5× 152 0.8× 116 1.0× 49 0.7× 10 448
Akinori Hirano Japan 9 315 1.2× 253 1.0× 134 0.7× 114 1.0× 39 0.5× 22 513
Sherwin Ting Singapore 12 436 1.7× 319 1.3× 286 1.4× 117 1.0× 119 1.7× 20 676
Ienglam Lei United States 14 374 1.4× 206 0.8× 109 0.6× 132 1.2× 36 0.5× 33 617
Laura Saludas Spain 10 178 0.7× 184 0.7× 155 0.8× 218 1.9× 35 0.5× 11 461
Vittoria Ionta Italy 12 310 1.2× 235 0.9× 69 0.3× 129 1.1× 45 0.6× 15 541
Alexander Mikryukov Canada 8 365 1.4× 236 0.9× 172 0.9× 92 0.8× 77 1.1× 9 533

Countries citing papers authored by Hiroko Iseoka

Since Specialization
Citations

This map shows the geographic impact of Hiroko Iseoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Iseoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Iseoka more than expected).

Fields of papers citing papers by Hiroko Iseoka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Iseoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Iseoka. The network helps show where Hiroko Iseoka may publish in the future.

Co-authorship network of co-authors of Hiroko Iseoka

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Iseoka. A scholar is included among the top collaborators of Hiroko Iseoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Iseoka. Hiroko Iseoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Miyagawa, Shigeru, Takuji Kawamura, Emiko Ito, et al.. (2024). Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch. Stem Cell Research & Therapy. 15(1). 73–73. 9 indexed citations
2.
Kawamura, Takuji, Toshimasa Uemura, Li Liu, et al.. (2022). Engineered three-dimensional cardiac tissues maturing in a rotating wall vessel bioreactor remodel diseased hearts in rats with myocardial infarction. Stem Cell Reports. 17(5). 1170–1182. 13 indexed citations
3.
Miyagawa, Shigeru, Satoshi Kainuma, Takuji Kawamura, et al.. (2022). Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy. Frontiers in Cardiovascular Medicine. 9. 950829–950829. 66 indexed citations
4.
Domae, Keitaro, Shigeru Miyagawa, Yasushi Yoshikawa, et al.. (2021). Clinical Outcomes of Autologous Stem Cell–Patch Implantation for Patients With Heart Failure With Nonischemic Dilated Cardiomyopathy. Journal of the American Heart Association. 10(13). e008649–e008649. 15 indexed citations
5.
Iseoka, Hiroko, Shigeru Miyagawa, Yoshiki Sakai, & Yoshiki Sawa. (2021). Cardiac fibrosis models using human induced pluripotent stem cell-derived cardiac tissues allow anti-fibrotic drug screening in vitro. Stem Cell Research. 54. 102420–102420. 17 indexed citations
6.
Iseoka, Hiroko, et al.. (2021). Rapid and sensitive mycoplasma detection system using image-based deep learning. Journal of Artificial Organs. 25(1). 50–58. 4 indexed citations
7.
Kainuma, Satoshi, Shigeru Miyagawa, Köichi Toda, et al.. (2021). Long-term outcomes of autologous skeletal myoblast cell-sheet transplantation for end-stage ischemic cardiomyopathy. Molecular Therapy. 29(4). 1425–1438. 23 indexed citations
8.
Iseoka, Hiroko, Shigeru Miyagawa, Atsuhiro Saito, Akima Harada, & Yoshiki Sawa. (2020). Role and therapeutic effects of skeletal muscle-derived non-myogenic cells in a rat myocardial infarction model. Stem Cell Research & Therapy. 11(1). 69–69. 8 indexed citations
9.
Yajima, Shin, Shigeru Miyagawa, Satsuki Fukushima, et al.. (2019). Prostacyclin Analogue–Loaded Nanoparticles Attenuate Myocardial Ischemia/Reperfusion Injury in Rats. JACC Basic to Translational Science. 4(3). 318–331. 19 indexed citations
10.
Ito, Emiko, Shigeru Miyagawa, Maki Takeda, et al.. (2019). Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application. Scientific Reports. 9(1). 1881–1881. 37 indexed citations
11.
Iseoka, Hiroko, Shigeru Miyagawa, Satsuki Fukushima, et al.. (2017). Pivotal Role of Non-cardiomyocytes in Electromechanical and Therapeutic Potential of Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissue. Tissue Engineering Part A. 24(3-4). 287–300. 55 indexed citations
12.
Takeda, Maki, Shigeru Miyagawa, Satsuki Fukushima, et al.. (2017). Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells. Tissue Engineering Part C Methods. 24(1). 56–67. 81 indexed citations
13.
Nishiguchi, Akihiro, Michiya Matsusaki, Hiroko Iseoka, et al.. (2016). Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. Acta Biomaterialia. 33. 110–121. 96 indexed citations
14.
Saito, Shunsuke, Shigeru Miyagawa, Taichi Sakaguchi, et al.. (2012). Myoblast Sheet Can Prevent the Impairment of Cardiac Diastolic Function and Late Remodeling After Left Ventricular Restoration in Ischemic Cardiomyopathy. Transplantation. 93(11). 1108–1115. 22 indexed citations
15.
Yamaguchi, Yoko, Hiroko Iseoka, Ayako Kobayashi, & Masatomo Maeda. (2004). The Carboxyl Terminal Sequence of Rat Transporter Associated with Antigen Processing (TAP)-Like (ABCB9) is Heterogeneous due to Splicing of Its mRNA. Biological and Pharmaceutical Bulletin. 27(1). 100–104. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert C. Coyle Breakdown of academic impact, for papers by Pablo Hofbauer Breakdown of academic impact, for papers by Maki Takeda Breakdown of academic impact, for papers by Jason Tchao Breakdown of academic impact, for papers by Akinori Hirano Breakdown of academic impact, for papers by Sherwin Ting Breakdown of academic impact, for papers by Ienglam Lei Breakdown of academic impact, for papers by Laura Saludas Breakdown of academic impact, for papers by Vittoria Ionta Breakdown of academic impact, for papers by Alexander Mikryukov
Rankless by CCL
2026